Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

@article{Jacobson2016DendriticCI,
  title={Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.},
  author={Jeffrey M. Jacobson and Jean-pierre Routy and Seth L. Welles and Mark A Debenedette and Irina Y. Tcherepanova and Jonathan Angel and David M. Asmuth and David Kidd Stein and J G Baril and Mehri S McKellar and David M Margolis and Benoit Trottier and Kenneth Wood and Charles A Nicolette},
  journal={Journal of acquired immune deficiency syndromes},
  year={2016},
  volume={72 1},
  pages={31-8}
}
BACKGROUND The genomic heterogeneity of HIV-1 impedes the ability of consensus sequences in vaccines to elicit effective antiviral immune responses. AGS-004 amplifies translation-competent RNA molecules encoding for Gag, Rev, Vpr, and Nef from the patient's autologous virus and loads them into dendritic cells. METHODS This phase IIB, multicenter, 2:1 randomized, double-blind, placebo-controlled study enrolled 54 HIV-1-infected patients on antiretroviral therapy with viral loads (VLs) <50… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Similar Papers

Loading similar papers…